Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer.

@article{Cura2002PhaseIA,
  title={Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer.},
  author={Jorge E Cura and Daniel P Blanzaco and Cecilia Brisson and Marco Antonio Cura and Rosa Cabrol and Luis Larrateguy and Carlos Parra Mendez and Jose Carlos Sechi and Jorge Solana Silveira and Elvira Theiller and Adolfo Rafael de Roodt and Juan Carlos Vidal},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2002},
  volume={8 4},
  pages={1033-41}
}
A Phase I clinical trial was performed on patients with solid tumors refractory to conventional therapy. Crotoxin was administered i.m. for 30 consecutive days at doses ranging from 0.03 to 0.22 mg/m(2). Patients entered the study after providing a written informed consent. Although 26 patients were entered only 23 were evaluated. Reversible, nonlimiting neuromuscular toxicity evidenced as diplopia because of pareses of the external ocular muscles was present in 13 patients. It started at doses… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 36 references

Molecular events in the myotoxic effects of phospholipases

  • J. E. Fletcher, H. S. Selistre de Araujo, C. L. Ownby
  • 1997

Similar Papers

Loading similar papers…